A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare public relations, indicated that he was having trouble procuring Epidiolex, recently approved for treating seizures caused by epilepsy:
Seeking Alpha published a headline to a short summary indicating that the company may be “facing supply issues”.
We reached out to company spokesperson Steve Schultz, who responded that “We have no supply issue whatsoever.” Schultz was familiar with the tweet but was not aware of the particular details. He explained that the company has seen some issues with insurance companies, and he indicated that specialty pharmacies are providing dosing only in line with what has been prescribed by the doctor.
GW Pharma is scheduled to report financial results for the quarter ending December 31 later this month.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.